Anti-Complement Treatment in Paroxysmal Nocturnal Hemoglobinuria: Where we Stand and Where we are Going

por Risitano, Antonio M
Publicado 2014

Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents

por Risitano, Antonio M, Rotoli, Bruno
Publicado 2008

Aplastic anemia: immunosuppressive therapy in 2010

por Risitano, Antonio M., Perna, Fabiana
Publicado 2011

Clonal Non-Malignant Hematological Disorders: Unraveling Molecular Pathogenic Mechanisms to Develop Novel Targeted Therapeutics

por Risitano, Antonio M., Selleri, Carmine
Publicado 2014

Infectious Agents and Bone Marrow Failure: A Causal or a Casual Connection?

por Giudice, Valentina, Risitano, Antonio M., Selleri, Carmine
Publicado 2021

The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: From a pathogenic mechanism to a therapeutic target

por Risitano, Antonio M., Frieri, Camilla, Urciuoli, Eleonora, Marano, Luana
Publicado 2022

Efficacy matters: broadening complement inhibition in COVID-19

por Mastellos, Dimitrios C, Skendros, Panagiotis, Calado, Rodrigo T, Risitano, Antonio M, Lambris, John D
Publicado 2021

Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes

por Sica, Michela, Rondelli, Tommaso, Ricci, Patrizia, De Angioletti, Maria, Risitano, Antonio M., Notaro, Rosario
Publicado 2017

Complement as a target in COVID-19?

por Risitano, Antonio M., Mastellos, Dimitrios C., Huber-Lang, Markus, Yancopoulou, Despina, Garlanda, Cecilia, Ciceri, Fabio, Lambris, John D.
Publicado 2020

Author Correction: Complement as a target in COVID-19?

por Risitano, Antonio M., Mastellos, Dimitrios C., Huber-Lang, Markus, Yancopoulou, Despina, Garlanda, Cecilia, Ciceri, Fabio, Lambris, John D.
Publicado 2020

Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria

por Risitano, Antonio M., Kulasekararaj, Austin G., Lee, Jong Wook, Maciejewski, Jaroslaw P., Notaro, Rosario, Brodsky, Robert, Huang, Mingjun, Geffner, Michael, Browett, Peter
Publicado 2020

Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab

por Kulasekararaj, Austin G., Risitano, Antonio M., Maciejewski, Jaroslaw P., Notaro, Rosario, Browett, Peter, Lee, Jong Wook, Huang, Mingjun, Geffner, Michael, Brodsky, Robert A.
Publicado 2021

Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT

por Risitano, Antonio M., Marotta, Serena, Ricci, Patrizia, Marano, Luana, Frieri, Camilla, Cacace, Fabiana, Sica, Michela, Kulasekararaj, Austin, Calado, Rodrigo T., Scheinberg, Phillip, Notaro, Rosario, Peffault de Latour, Regis
Publicado 2019

The first case of COVID-19 treated with the complement C3 inhibitor AMY-101

por Mastaglio, Sara, Ruggeri, Annalisa, Risitano, Antonio M., Angelillo, Piera, Yancopoulou, Despina, Mastellos, Dimitrios C., Huber-Lang, Markus, Piemontese, Simona, Assanelli, Andrea, Garlanda, Cecilia, Lambris, John D., Ciceri, Fabio
Publicado 2020

Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria

por Hillmen, Peter, Muus, Petra, Röth, Alexander, Elebute, Modupe O, Risitano, Antonio M, Schrezenmeier, Hubert, Szer, Jeffrey, Browne, Paul, Maciejewski, Jaroslaw P, Schubert, Jörg, Urbano-Ispizua, Alvaro, de Castro, Carlos, Socié, Gérard, Brodsky, Robert A
Publicado 2013

Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 rand...

por Peffault de Latour, Régis, Brodsky, Robert A., Ortiz, Stephan, Risitano, Antonio M., Jang, Jun H., Hillmen, Peter, Kulagin, Alexander D., Kulasekararaj, Austin G., Rottinghaus, Scott T., Aguzzi, Rasha, Gao, Xiang, Wells, Richard A., Szer, Jeff
Publicado 2020

Factor H interferes with the adhesion of sickle red cells to vascular endothelium: a novel disease-modulating molecule

por Lombardi, Elisabetta, Matte, Alessandro, Risitano, Antonio M., Ricklin, Daniel, Lambris, John D., De Zanet, Denise, Jokiranta, Sakari T., Martinelli, Nicola, Scambi, Cinzia, Salvagno, Gianluca, Bisoffi, Zeno, Colato, Chiara, Siciliano, Angela, Bortolami, Oscar, Mazzuccato, Mario, Zorzi, Francesco, De Marco, Luigi, De Franceschi, Lucia
Publicado 2019

The EHA Research Roadmap: Anemias

por Iolascon, Achille, Rivella, Stefano, Anagnou, Nicholas P., Camaschella, Clara, Swinkels, Dorine, Muckenthaler, Martina U., Porto, Graça, Barcellini, Wilma, Andolfo, Immacolata, Risitano, Antonio M., Kattamis, Antonis, Cappellini, Maria Domenica, Taher, Ali T., De Franceschi, Lucia, Rees, David, Russo, Roberta, Tamary, Hannah, Stauder, Reinhard, Girelli, Domenico
Publicado 2021

Characterization of breakthrough hemolysis events observed in the phase III randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria

por Brodsky, Robert A., de Latour, Régis Peffault, Rottinghaus, Scott T., Röth, Alexander, Risitano, Antonio M., Weitz, Ilene C., Hillmen, Peter, Maciejewski, Jaroslaw P., Szer, Jeff, Lee, Jong Wook, Kulasekararaj, Austin G., Volles, Lori, Damokosh, Andrew I., Ortiz, Stephan, Shafner, Lori, Liu, Peng, Hill, Anita, Schrezenmeier, Hubert
Publicado 2020

Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy

por Mastellos, Dimitrios C., Pires da Silva, Bruno G.P., Fonseca, Benedito A.L., Fonseca, Natasha P., Auxiliadora-Martins, Maria, Mastaglio, Sara, Ruggeri, Annalisa, Sironi, Marina, Radermacher, Peter, Chrysanthopoulou, Akrivi, Skendros, Panagiotis, Ritis, Konstantinos, Manfra, Ilenia, Iacobelli, Simona, Huber-Lang, Markus, Nilsson, Bo, Yancopoulou, Despina, Connolly, E. Sander, Garlanda, Cecilia, Ciceri, Fabio, Risitano, Antonio M., Calado, Rodrigo T., Lambris, John D.
Publicado 2020